(Q36621049)

English

ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients

scientific article published on January 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

7

object named as

Linch DC

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Anthony H. Goldstone

6

object named as

Goldstone AH

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Watts MJ

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Ings SJ

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Leverett D

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

MacMillan A

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Devereux S

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 January 2000

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

82

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

278-282

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363271

30 September 2017

A comparison of peripheral blood stem cell mobilisation after chemotherapy with cyclophosphamide as a single agent in doses of 4 g/m2 or 7 g/m2 in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363271

30 September 2017

Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphom

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363271

28 June 2018

Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363271

20 September 2018

Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral blood stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10646877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.1999.0915

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36621049&oldid=2199105341"